Evidence map›Paper›PMID 37848002›Full record

ReviewActa haematologica2024

Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia.

Susanne Saussele, Paul La Rosée, Alexander Kiani, Wilhelm Haverkamp, Kathleen Jentsch-Ullrich, Frank Stegelmann, Christina Rieger, Cornelius F Waller, Georg-Nikolaus Franke, Christian Junghanss and 3 more

Erratum issuedOpen access · greenAbstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Dose Optimization of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.Clinical pharmacology : advances and applications · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Susanne SausseleDepartment of Haematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Paul La RoséeKlinik für Innere Medizin II, Schwarzwald-Baar-Klinikum, Villingen-Schwenningen, Germany.
Alexander KianiMedizinische Klinik IV, Klinikum Bayreuth GmbH, Bayreuth, Germany.
Wilhelm HaverkampDepartment of Cardiology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany.
Kathleen Jentsch-UllrichGemeinschaftspraxis Hämatologie und Onkologie, Magdeburg, Germany.
Frank StegelmannDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
Christina RiegerHematology and Oncology Germering, Germering, Germany.
Cornelius F WallerInternal Medicine I, Haematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center and Faculty of Medicine, Freiburg, Germany.
Georg-Nikolaus FrankeDepartment for Hematology, Cellular Therapies and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany.
Christian JunghanssHematology, Oncology, Palliative Medicine, Department of Medicine, Clinic III, Rostock University Medical Center, Rostock, Germany.
Rudolf KirchmairMedical University of Innsbruck, University Hospital of Internal Medicine, Cardiology and Angiology, Innsbruck, Austria.
Markus TheurlMedical University of Innsbruck, University Hospital of Internal Medicine, Cardiology and Angiology, Innsbruck, Austria.
Philipp le CoutreDepartment of Medicine, Hematology and Oncology, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Charité - Universitätsmedizin Berlin · DEComprehensive Cancer Center Erlangen · DEFreie Universität Berlin · DEHeidelberg University · DEPraxis für Hämatologie und Onkologie · DESchwarzwald-Baar Klinikum · DEUniversity Hospital Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBased on the new data from the primary analysis of the OPTIC (Optimizing Ponatinib Treatment in CP-CML) trial on dose optimization of ponatinib in patients with chronic phase (CP)-CML, the German consensus paper on ponatinib published in 2020 (Saussele S et al., Acta Haematol. 2020) has been updated in this addendum. SUMMARY: Focus is on the update of efficacy and safety of ponatinib, reflecting the new data set, as well as the update of the benefit-risk assessment and recommendations for ponatinib starting dose in CP-CML - provided that the decision to use ponatinib has already been made. Furthermore, based on OPTIC and additional empirical data, the expert panel collaborated to develop a decision tree for ponatinib dosing, specifically for intolerant and resistant patients. The recommendations on cardiovascular management have also been updated based on the most recent 2021 guidelines of the European Society of Cardiology (ESC) on cardiovascular disease prevention in clinical practice. KEY MESSAGES: The OPTIC data confirm the high efficacy of ponatinib in patients with CP-CML and provide the basis for individualized dose adjustment during the course of treatment.

Indexed as

ImidazolesLeukemia, Myelogenous, Chronic, BCR-ABL PositivePyridazinesAntineoplastic AgentsCardiovascular DiseasesGermanyHumansPractice Guidelines as TopicProtein Kinase InhibitorsAntineoplastic AgentsImidazolesponatinibProtein Kinase InhibitorsPyridazinesCardiovascular managementChronic myeloid leukemiaConsensus paperDosing regimensPonatinib

Identifiers

PMID37848002
PMCPMC11152025
OpenAlexW4387699900

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.